Anzupgo is indicated for the treatment of moderate to severe chronic hand eczema (CHE)
ANZUPGO — LEO PHARMA AS, approved 2026-06-30 (NDA219155).
165 reports across the top reactions. These are spontaneously reported events from the FDA Adverse Event Reporting System — they reflect reporting volume, not incidence or frequency, and a report does not mean the drug caused the event.